This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berendsen, H. H. Articles by The, H. T. Search for Related Content PubMed PubMed Citation Articles by Berendsen, H. H. Articles by The, H. T.

Characterization of Three Small Cell Lung Cancer Cell Lines Established from One Patient during Longitudinal Follow-up¹

Department of Clinical Immunology [H. H. B., L. D. L., G. M., H. T. T.], Department of Pulmonology [H. H. B., P. E. P., H. J. S.], Department of Medical Oncology [E. G. E. D. V., N. H. M.], Department of Human Genetics [B. D. J., C. H. C. M. B.], and Department of Pathology [S. P.], University Hospital, Groningen, The Netherlands

Three classic-type, small cell lung cancer cell lines (GLC-14, GLC-16, and GLC-19) have been established from one patient during longitudinal follow-up. During this period the tumor changed from sensitive to completely resistant to (chemo)therapy. A phenotypical and functional characterization of the different cell lines is given in combination with the matching clinical data.

(a) The cell lines have been compared with the biopsies from which they were derived. There was a good match between the morphological, biochemical, and immunohistological findings in the cell lines as compared to those obtained in the biopsies. When the biopsy and cell line (GLC-14) obtained before the start of therapy were compared to the biopsies and cell lines (GLC-16 and GLC-19) acquired after the first and second reinduction therapy, respectively, no major changes could be observed. The only clear alteration was the loss of a neuroendocrine antigen (defined by monoclonal antibody MOC-51) in the posttherapy specimens.

(b) The doxorubicin, melphalan, and etoposide sensitivity in vitro reflected the clinically observed development of resistance to treatment. The cell line (GLC-14) established before the start of therapy was more sensitive than the lines (GLC-16 and GLC-19) obtained after treatment.

It is concluded that the cell lines described in this paper represent a well-characterized in vitro model in which the development of drug resistance in small cell lung cancer can be studied.

¹ This study was supported by a grant from the Koningin Wilhelmina Fonds.

² To whom requests for reprints should be addressed, at the Department of Clinical Immunology, University Hospital, Oostersingel 59, Groningen, The Netherlands.

Received 8/25/87. Revised 7/18/88. Accepted 8/24/88.

This article has been cited by other articles:

				N. Pedersen, S. Mortensen, S. B. Sorensen, M. W. Pedersen, K. Rieneck, L. F. Bovin, and H. S. Poulsen Transcriptional Gene Expression Profiling of Small Cell Lung Cancer Cells Cancer Res., April 15, 2003; 63(8): 1943 - 1953. [Abstract] [Full Text] [PDF]

				E. L. Lund, C. Thorsen, M. W. B. Pedersen, N. Junker, and P. E. G. Kristjansen Relationship Between Vessel Density and Expression of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Small Cell Lung Cancer in Vivo and in Vitro Clin. Cancer Res., November 1, 2000; 6(11): 4287 - 4291. [Abstract] [Full Text] [PDF]

				K. Helin, K. Holm, A. Niebuhr, H. Eiberg, N. Tommerup, S. Hougaard, H. S. Poulsen, M. Spang-Thomsen, and P. Norgaard Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma PNAS, June 24, 1997; 94(13): 6933 - 6938. [Abstract] [Full Text] [PDF]